US › Healthcare

Novocure Ltd (NVCR)

US · Healthcare · Medical Devices

$16.27+6.20%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$183.6M
Revenue YoY
+15.6%
Net profit
$-15.7M
Profit YoY
+61.0%
EPS
$-0.13
EPS estimate
$-0.30
Net margin
-8.5%

EPS came in at -0.13 against a street estimate of -0.30 — a beat of 56.7%.

Key statistics

Market cap
$1.73B
Forward P/E
909.1
P/B
5.11
Book value
$2.90
EPS (TTM)
$-1.30
52-week high
$21.45
52-week low
$9.82
50-day MA
$16.53
200-day MA
$13.79
Beta
0.94

Analyst view

Analysts rate Novocure Ltd a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $27.14.

Shareholding

Insiders
9.96%
Institutions
86.94%

Largest institutional holders

FundStake
FMR Inc14.74%
BlackRock Inc11.39%
Vanguard Group Inc9.46%
Soleus Capital Management, L.P.9.06%
Vanguard Portfolio Management, LLC5.40%
Vanguard Capital Management, LLC4.04%
Morgan Stanley - Brokerage Accounts3.92%
Wells Fargo & Co2.55%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Novocure Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.